Not Yet RecruitingPhase 4

REDUCER Trial (TXA in Urethroplasty)

United States40 participantsStarted 2026-05-01

Plain-language summary

This study will test whether tranexamic acid (TXA), a medication used to reduce bleeding, can decrease blood loss in patients having urethroplasty. Participants will be randomly assigned to receive either a single intravenous dose of TXA at the start of anesthesia or standard care without TXA. Researchers will compare hemoglobin change after surgery as well as estimated blood loss and complications.

Who can participate

Age range18 Years

SexMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Adult patients (≥18 years old) * Undergoing urethroplasty for urethral stricture disease * Ability to provide informed consent Exclusion Criteria: * Known contraindication to tranexamic acid (TXA) * History of thromboembolic disease (e.g., deep vein thrombosis, pulmonary embolism, stroke) * Known bleeding disorder or coagulopathy * Current use of anticoagulation that cannot be safely held perioperatively * Severe renal impairment * Allergy or hypersensitivity to tranexamic acid * History of seizures * Inability to provide informed consent

What they're measuring

Change in hemoglobin

Timeframe: Baseline to postoperative day 5-7

Trial details

NCT IDNCT07501884

SponsorAmjad Alwaal, MD, MSc, FRCSC, FACS

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2026-12-31

Contact for this trial

Amjad Alwaal, MD, MSc, FACS

973-972-4418 amjad.alwaal@rutgers.edu

View on ClinicalTrials.gov More Urethral Stricture trials